A recent article on Medscape explores the potential of circulating tumor DNA (ctDNA) to guide clinical decisions in gastrointestinal cancers. Here are three key insights from the discussion:
- ctDNA analysis offers a promising tool for precision medicine, enabling more accurate monitoring of tumor dynamics and treatment responses in real-time.
- The use of ctDNA can potentially detect minimal residual disease and early recurrence, providing a significant advantage in the timely management of gastrointestinal cancers.
- Despite its potential, the integration of ctDNA into routine clinical practice faces challenges, including standardization of testing protocols and validation of clinical utility.